

NCCN Guidelines for Multiple Myeloma V.2.2020 – Follow-Up 9/27/19

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	Abstain	Absent
<b>MYEL-F (1 of 3)</b>  Internal request: Request to include daratumumab in combination with bortezomib/thalidomide/dexamethasone for the treatment of transplant eligible patients with newly diagnosed multiple myeloma based on FDA approval.  External request: Submission from Janssen respectfully requests the inclusion of daratumumab in combination with bortezomib/thalidomide/dexamethasone for the treatment of transplant eligible patients with newly diagnosed multiple myeloma.	In response to the FDA approval, the panel consensus was to include daratumumab in combination with bortezomib/thalidomide/dexamethasone as Useful in Certain Circumstances as therapy for transplant eligible patients with newly diagnosed multiple myeloma.  See Submission for references.	20	0	0	9